Hemispherx BioPharma, Inc Share Price Nyse
Equities
US42366C3016
Biotechnology & Medical Research
Sales 2024 * | 113K 8.93M | Sales 2025 * | 1.78M 140M | Capitalization | 19.94M 1.57B |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.89B | Net income 2025 * | -25M -1.97B | EV / Sales 2024 * | 176 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-0.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 03/04/22 |
Chief Tech/Sci/R&D Officer | - | 31/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 27/03/23 |
William Mitchell
CHM | Chairman | 89 | 30/06/98 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |